Rifaximin for reducing recurrent episodes of overt hepatic encephalopathy

Published on 02 May 2019
Last Updated on 02 May 2019

Guidance Recommendations

The Ministry of Health's Drug Advisory Committee has recommended:

• Rifaximin 550 mg tablet as add-on therapy to lactulose for reducing recurrent episodes of overt hepatic encephalopathy.

Subsidy status

Rifaximin 550 mg tablet is recommended for inclusion on the MOH Standard Drug List (SDL) for the abovementioned indication.

Rifaximin for reducing overt hepatic encephalopathy (2 May 2019) [PDF, 467 KB]

Rifaximin Plain English Summary (2 May 2019) [PDF, 31 KB]